Research programme: tissue protection technology - Lundbeck/Warren Pharmaceuticals

Drug Profile

Research programme: tissue protection technology - Lundbeck/Warren Pharmaceuticals

Alternative Names: Tissue protection technology research programme - Warren Pharmaceuticals/Lundbeck; Tissue-protective cytokines

Latest Information Update: 23 Oct 2007

Price : $50

At a glance

  • Originator Warren Pharmaceuticals
  • Developer Lundbeck A/S; Warren Pharmaceuticals
  • Class Cytokines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease; Neuroprotection

Most Recent Events

  • 23 Oct 2007 A lead compound from this research programme enters clinical trials
  • 24 Aug 2004 A preclinical study has been added to the Neurological disorders pharmacodynamics section
  • 18 Sep 2002 Preclinical trials in Neuroprotection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top